The following information is intended for healthcare professionals only. Please confirm that you are a healthcare professional by clicking "Yes" or "No" to be redirected to the Biotest corporate site.
For HCPs only.
Cytotect CP® is indicated for prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly transplant recipients.1
The concomitant use of adequate virostatic agents should be considered for CMV prophylaxis.1 Basic Information available here.
Amplify your CMV control
When targeting CMV following transplantation, watch how an ensemble approach can amplify prophylaxis in immunosuppressed patients.
CMV infection...
- Remains a major cause of morbidity and mortality in transplant patients2–4
- Is associated with significantly decreased survival in solid organ transplant5
- Is associated with an increased risk of organ rejection2,6,7
Antiviral monotherapy may provide insufficient protection against CMV
Limitations of the virostatic mode of action
- Antivirals block viral replication, but are unable to destroy intra- or extracellular viruses, which may result in a rebound effect when antiviral therapy is discontinued2,8,9
- Antiviral drugs are unable to prevent infection of other cells or organs by free virus particles9
Cytotect CP® has a specific and targeted mode of action,1,10 complementary to antivirals
Cytotect CP® prevents cell penetration of the virus by binding CMV surface antigens1,10
Cytotect CP® labels CMV and presents it for phagocytosis (internalization and destruction by immune cells)1,10
Cytotect CP® can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses1,10
Cytotect CP® inhibits pro-inflammatory cells, decreasing cytokine production and immune-mediated damage1,6,10
Go backstage to learn more about Cytotect CP®'s mode of action
Cytotect CP® combination prophylaxis…
reduces CMV infection and disease in lung and heart transplant patients11,12
Prevention of CMV infection and disease
reduction in CMV infection
with Cytotect CP® combination prophylaxis in lung transplant patients versus antiviral monotherapy11
reduction in CMV disease with Cytotect CP® combination prophylaxis in heart transplant patients versus monotherapy with Cytotect CP®12
helps prevent organ rejection11,12
Prevention of organ rejection
reduction in BOS
(bronchiolitis obliterans syndrome) with Cytotect CP® combination prophylaxis in lung transplant patients11
relative risk reduction for CAV (cardiac allograft vasculopathy) with Cytotect CP® combination prophylaxis in heart transplant patients (ARR: 6.4%)12
improves patient survival11
Improvement of survival
improvement in 3-year survival with Cytotect CP® combination prophylaxis in lung transplant patients versus antiviral monotherapy11
Cytotect CP® is characterized by a favorable tolerability profile10
Cytotect CP®:
Highly purified immunoglobulin preparation with a standardized high titer against CMV13,14
Complementary to the actions of virostatic drugs13,14
Approved for prophylaxis of clinical manifestations of CMV infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients1,9
Concomitant use of adequate virostatic agents should be considered1
Can be used for prophylaxis of clinical manifestations of CMV infection1, which includes pre-emptive management of asymptomatic CMV infection
Simple dosing regimen1
Does not contain sucrose, glucose, or maltose1 - excipients associated with acute renal failure
Cytotect CP® has shown favorable tolerability in clinical trials1 and in RWE10
No adverse reactions to Cytotect CP® have been identified in the Biotest CMVIG clinical trial program1
Data from post-marketing experience underline the positive safety profile of Cytotect CP®10
For more information, please refer to the most recent Summary of Product Characteristics.
will be playing at DTG 2024, 7-9 November, Freiburg, Germany in: Now playing at DTG 2024, 7-9 November, Freiburg, GermanyPlayed at DTG 2024, 7-9 November, Freiburg, Germany
:
:
:
Playing again at EBMT 2025, 30 March - 2 April, Florence, Italy: Now playing at EBMT 2025, 30 March - 2 April, Florence, ItalyPlayed at EBMT 2025, 30 March - 2 April, Florence, Italy
:
:
:
Playing again at ISHLT 2025, 27-30 April, Boston, USA: Now playing at ISHLT 2025, 27-30 April, Boston, USAPlayed at ISHLT 2025, 27-30 April, Boston, USA
:
:
:
References:
- Cytotect CP® Biotest. Summary of Product Characteristics.
- Snydman DR, et al. Transplant Proc. 2011;43(3 Suppl):S1–17.
- Ljungman P, et al. Hematol Oncol Clin North Am. 2011;25(1):151–69.
- Walker CM, et al. Biol Blood Marrow Transplant. 2007;13(9):1106–15.
- Desai R, et al. Transplantation. 2015;99(9):1989–94.
- Kornberg A, World J Hepatol. 2015;7(11):1494–508.
- Preiksaitis JK, et al. Am J Transplant. 2005;5(2):218–27.
- Fishman JA, Am J Transplant. 2017;17(4):856–879.
- Andreoni KA, et al. J Med Virol. 2002;67(1):33–40.
- Grossi P, et al. Transplantation. 2016;100(Suppl 3):S1–4.
- Ruttmann E, et al. Transplantation. 2006;81(10):1415–20.
- Bonaros NE, et al. Transplantation. 2004;77(6):890–897.
- Lachmann R, et al. PLoS one. 2018;13(7):e0200267.
- Adland E, et al. Front Microbiol. 2015;6:1016.
Copyright © 2024 Biotest AG. All rights reserved. Biotest AG is proprietor of all trademarks and tradenames used on this website.